Both TYK2 and types I and III interferon are involved in CLE pathophysiology. In a phase II trial of patients with SLE and baseline CLASI-A score ≥10, patients treated with any of three doses of ...
The randomised, double-blind, placebo-controlled WILLOW study (NCT05162586) was investigating the therapy in 456 patients with cutaneous lupus erythematosus (CLE) and SLE. The study investigated three ...
Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback